JP6947642B2 - 抗がん性融合ポリペプチド - Google Patents

抗がん性融合ポリペプチド Download PDF

Info

Publication number
JP6947642B2
JP6947642B2 JP2017560331A JP2017560331A JP6947642B2 JP 6947642 B2 JP6947642 B2 JP 6947642B2 JP 2017560331 A JP2017560331 A JP 2017560331A JP 2017560331 A JP2017560331 A JP 2017560331A JP 6947642 B2 JP6947642 B2 JP 6947642B2
Authority
JP
Japan
Prior art keywords
ser
arg
lys
tyr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017560331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018519803A5 (enExample
JP2018519803A (ja
Inventor
マーロン ヒンナー
マーロン ヒンナー
アイバ ラシダ シハム ベル
アイバ ラシダ シハム ベル
クリスティーヌ ローテ
クリスティーヌ ローテ
シェーン オルヴィル
シェーン オルヴィル
コリンナ シュロッサー
コリンナ シュロッサー
Original Assignee
ピエリス ファーマシューティカルズ ゲーエムベーハー
ピエリス ファーマシューティカルズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピエリス ファーマシューティカルズ ゲーエムベーハー, ピエリス ファーマシューティカルズ ゲーエムベーハー filed Critical ピエリス ファーマシューティカルズ ゲーエムベーハー
Publication of JP2018519803A publication Critical patent/JP2018519803A/ja
Publication of JP2018519803A5 publication Critical patent/JP2018519803A5/ja
Application granted granted Critical
Publication of JP6947642B2 publication Critical patent/JP6947642B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017560331A 2015-05-18 2016-05-18 抗がん性融合ポリペプチド Active JP6947642B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15167927 2015-05-18
EP15167927.1 2015-05-18
EP16150508.6 2016-01-08
EP16150508 2016-01-08
PCT/EP2016/061071 WO2016184882A1 (en) 2015-05-18 2016-05-18 Anti-cancer fusion polypeptide

Publications (3)

Publication Number Publication Date
JP2018519803A JP2018519803A (ja) 2018-07-26
JP2018519803A5 JP2018519803A5 (enExample) 2019-06-20
JP6947642B2 true JP6947642B2 (ja) 2021-10-13

Family

ID=56134305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017560331A Active JP6947642B2 (ja) 2015-05-18 2016-05-18 抗がん性融合ポリペプチド

Country Status (22)

Country Link
US (2) US10913778B2 (enExample)
EP (2) EP3298030B1 (enExample)
JP (1) JP6947642B2 (enExample)
KR (1) KR102685748B1 (enExample)
CN (1) CN108112253B (enExample)
AU (1) AU2016262845B2 (enExample)
CA (1) CA2980838A1 (enExample)
DK (1) DK3298030T5 (enExample)
ES (1) ES2938525T3 (enExample)
FI (1) FI3298030T3 (enExample)
HR (1) HRP20230145T1 (enExample)
HU (1) HUE061108T2 (enExample)
LT (1) LT3298030T (enExample)
MX (1) MX390894B (enExample)
PL (1) PL3298030T3 (enExample)
RS (1) RS64002B1 (enExample)
RU (2) RU2754466C2 (enExample)
SG (1) SG11201707426SA (enExample)
SI (1) SI3298030T1 (enExample)
SM (1) SMT202300026T1 (enExample)
WO (1) WO2016184882A1 (enExample)
ZA (1) ZA201706061B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
PH12017501583B1 (en) * 2015-05-04 2023-01-20 Pieris Pharmaceuticals Gmbh Novel proteins specific for cd137
MX2018000447A (es) 2015-07-15 2018-08-15 Pieris Pharmaceuticals Gmbh Novedosas proteinas especificas para lag-3.
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CA3047070A1 (en) * 2017-01-03 2018-07-12 F.Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
EP3565842A1 (en) 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
JP7225116B2 (ja) * 2017-01-18 2023-02-20 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｌａｇ－３に対する結合親和性を有するリポカリンムテイン
WO2018134279A1 (en) * 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
CA3082297A1 (en) * 2017-11-13 2019-05-16 Crescendo Biologics Limited Molecules that bind to cd137 and psma
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
MX2020010015A (es) 2018-03-26 2021-01-15 4Sc Ag Combinacion que comprende inhibidor de hdac y agonista de cd137 para la terapia del cancer.
RS64343B9 (sr) * 2018-07-31 2023-11-30 Pieris Pharmaceuticals Gmbh Novi fuzioni protein specifičan za cd137 i pd-l1
JP7476219B2 (ja) 2019-02-26 2024-04-30 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質
CN113939307A (zh) * 2019-03-29 2022-01-14 皮里斯制药有限公司 脂质运载蛋白突变蛋白的吸入施用
CN113677403B (zh) * 2019-04-12 2024-12-27 豪夫迈·罗氏有限公司 包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
BR112021021271A2 (pt) * 2019-04-23 2021-12-21 Lg Chemical Ltd Polipeptídeo de fusão compreendendo região fc de imunoglobulina e gdf15
CN114245807B (zh) * 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
TWI860386B (zh) * 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
WO2023036043A1 (zh) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 抗癌结合分子及其应用
PE20251544A1 (es) * 2022-09-21 2025-06-05 Seagen Inc Nueva proteina de fusion especifica para cd137 y cd228
WO2026145795A1 (zh) * 2025-01-06 2026-07-09 湖南中晟全肽生物科技股份有限公司 一种gpc3靶向结合多肽及其药物偶联物与应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
AU696387B2 (en) 1994-05-18 1998-09-10 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
JP3839667B2 (ja) 1998-06-08 2006-11-01 エフ．ホフマン−ラ ロシュ アーゲー 慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＮＦ−アルファ及びリバビリンの使用
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
AU2001294617A1 (en) 2000-09-21 2002-04-02 University Of Massachusetts Method of inducing apoptosis in lymphoid cells
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
US7118915B2 (en) 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
AU2006294644A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007137170A2 (en) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
CN101516907B (zh) 2006-08-01 2015-08-26 皮里斯股份公司 泪液脂质运载蛋白的突变蛋白及其获得方法
DE602007009995D1 (de) 2006-08-01 2010-12-02 Pieris Ag Muteine von tearlipocalin und verfahren zu deren gewinnung
AU2008275985B2 (en) 2007-07-17 2013-09-19 E. R. Squibb & Sons, L.L.C. Monoclonal antibodies against Glypican-3
EP2225268B1 (en) 2007-10-19 2012-08-29 Abbott Laboratories Immunoassays and kits for the detection of ngal
US8420051B2 (en) 2008-06-24 2013-04-16 Technische Universitaet Meunchen Muteins of hNGAL and related proteins with affinity for a given target
BR112012013662B1 (pt) 2009-12-07 2022-08-02 Pieris Pharmaceuticals Gmbh Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
AU2011290751B2 (en) 2010-08-16 2015-08-13 Pieris Ag Binding proteins for Hepcidin
NZ729044A (en) * 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
CA2817779C (en) 2010-11-15 2019-02-19 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
WO2013174783A1 (en) * 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
SG11201504600UA (en) * 2012-12-10 2015-07-30 Hutchinson Fred Cancer Res Methods for screening
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
CN104140974B (zh) * 2013-05-08 2017-09-29 科济生物医药（上海）有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
AU2015205530B8 (en) 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
MX380176B (es) * 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
SG11201705278QA (en) 2015-01-28 2017-07-28 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
EP3259282A1 (en) 2015-02-18 2017-12-27 Sanofi Novel proteins specific for pyoverdine and pyochelin
RU2727165C2 (ru) 2015-05-04 2020-07-21 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
PH12017501583B1 (en) 2015-05-04 2023-01-20 Pieris Pharmaceuticals Gmbh Novel proteins specific for cd137
EP3298029A1 (en) * 2015-05-18 2018-03-28 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白

Also Published As

Publication number Publication date
RU2754466C2 (ru) 2021-09-02
AU2016262845B2 (en) 2020-07-23
AU2016262845A1 (en) 2018-01-04
WO2016184882A1 (en) 2016-11-24
EP3298030A1 (en) 2018-03-28
MX2017014716A (es) 2018-06-28
RU2017135539A (ru) 2019-06-18
DK3298030T5 (en) 2024-10-07
CN108112253A (zh) 2018-06-01
FI3298030T3 (fi) 2023-02-22
BR112017020445A2 (pt) 2018-07-03
SI3298030T1 (sl) 2023-05-31
RU2017135539A3 (enExample) 2019-11-29
US10913778B2 (en) 2021-02-09
RU2021119777A (ru) 2021-08-16
CN108112253B (zh) 2022-09-23
US20180148485A1 (en) 2018-05-31
DK3298030T3 (en) 2023-02-06
EP4219535A1 (en) 2023-08-02
RS64002B1 (sr) 2023-03-31
LT3298030T (lt) 2023-02-27
KR20180002855A (ko) 2018-01-08
SG11201707426SA (en) 2017-10-30
JP2018519803A (ja) 2018-07-26
US20210403516A1 (en) 2021-12-30
KR102685748B1 (ko) 2024-07-18
MX390894B (es) 2025-03-21
ES2938525T3 (es) 2023-04-12
SMT202300026T1 (it) 2023-03-17
HRP20230145T1 (hr) 2023-04-28
ZA201706061B (en) 2022-05-25
EP3298030B1 (en) 2023-01-18
PL3298030T3 (pl) 2023-05-08
CA2980838A1 (en) 2016-11-24
US11919931B2 (en) 2024-03-05
HUE061108T2 (hu) 2023-05-28

Similar Documents

Publication Publication Date Title
US11919931B2 (en) Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)
JP6783797B2 (ja) 抗がん融合ポリペプチド
RU2628699C2 (ru) Trail r2-специфические мультимерные скаффолды
JP7476219B2 (ja) Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質
TWI837156B (zh) 新穎的cd137及pd-l1特異性融合蛋白
KR20230020443A (ko) 4-1bb 표적화 다량체 면역조절제
BR112017020445B1 (pt) Proteína de fusão, molécula de ácido nucleico, célula hospedeira, método de produção de uma proteína de fusão, uso de uma ou mais proteínas de fusão e composição farmacêutica
HK1249526B (en) Anti-cancer fusion polypeptide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201201

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210820

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210916

R150 Certificate of patent or registration of utility model

Ref document number: 6947642

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250